CWBR News and Press, CohBar Inc. From 05/17/21

CohBar (CWBR): Q1 GAAP EPS of -$0.07 misses by $0.02.CohBar had cash and investments of $17.8 million as of March 31, 2021, compared to $21.0 million as of December 31, 2020. The cash burn for the quarter ended March 31, 2021, was approximately $4.2 million.  Press Release For fur...

MENLO PARK, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the first quarter ended March 3...

MENLO PARK, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its first quarter 202...

CohBar (CWBR) has appointed Joseph J. Sarret, M.D., J.D. as CEO and Director, effective May 3, 2021.In addition, Mr. David Greenwood, a current Director with 40 years of financial and operational experience in biotechnology and investment banking, has assumed the role of Chairman of the ...

CohBar, Inc. is an interesting early-clinical-stage biotechnology company developing mitochondrial-based therapeutics for treating chronic and age-related diseases including nonalcoholic steatohepatitis and obesity, amongst others. CohBar's pipeline consists of the lead comp...

Sypris Solutions SYPR +34% on winning contract for deep space program.Silicon Laboratories SLAB +16% as Skyworks buys Infrastructure & Automotive business of the Company.LM Funding America LMFA +14% on plans to purchase up to $2.0M in digital assets.Sigma Lab...

MENLO PARK, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that the last subject has completed their final visit ...

MENLO PARK, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer Steven Engle will pre...

The following slide deck was published by CohBar, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: CohBar, Inc. 2020 Q4 - Results - Earnings Call Presentation

CohBar, Inc. (CWBR) Q4 2020 Earnings Conference Call March 30, 2021 05:00 PM ET Company Participants Jordyn Tarazi - Director of Investor Relations Jeff Biunno - Chief Financial Officer Steve Engle - Chief Executive Officer Ken Cundy - Chief Scientific Officer Conference Call Participants Mic...